Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Sangamo Therapeutics Inc
SGMO
Healthcare
Biotechnology
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended...
neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:SGMO)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
•••
Jonathon Brown
X
View Profile
View Bullboard History
Post by
Jonathon Brown
on Nov 21, 2024 6:55am
Buzz on the Bullboards: Bombardier, world woes, a smart fridge, and top shelf weed
A highlight of the week was Bombardier (TSX:BBD), which reported impressive growth in its Q3 2024 results.
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 19, 2024 4:15pm
New Press Release - Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Sangamo plans to initiate enrollment of patients in the Phase 1/2 study for ST-503 in mid-2025 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for...
read article.
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 12, 2024 4:03pm
New Press Release - Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Announced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in Fabry disease, using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 04, 2024 4:22pm
New Press Release - Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2024 financial results after the market close on Tuesday, November 12, 2024. The company will hold a conference call at 4:30 p.m. Eastern on...
read article.
(217)
•••
askretka
X
View Profile
View Bullboard History
Post by
askretka
on Nov 01, 2024 12:04pm
Fabry gene disease therapy will save millions and millions
Expecting an announcement on Fabry disease partnership soon next week or so. Should give the stock a nice increase. Basically the cost of current ERT enzyme replacement therapy is 10 million plus
...more
(217)
•••
askretka
X
View Profile
View Bullboard History
Post by
askretka
on Oct 29, 2024 9:15am
8$ Target 28 October Jeffries Report
You can find it on stocktwits, don't have a link unfortunately. Fabry deal expected soon to extend cash runway. CHEERS!!!!!!!!!!!!!!!!!!!!!!
(217)
•••
askretka
X
View Profile
View Bullboard History
Post by
askretka
on Oct 28, 2024 9:03pm
Up 36% today wow
Hope some people got onboard. Sorry I was too busy to do a good post on it before it took off. CHEERS!!!!!!!!!!!!!!!
(227)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Oct 22, 2024 10:00am
Sangamo Therapeutics Announces Alignment With FDA on Acceler
News; $SGMO Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025- U.S. Food and Drug Administration (FDA
...more
(217)
•••
askretka
X
View Profile
View Bullboard History
Post by
askretka
on Oct 14, 2024 5:41pm
Up 10.75% today I.mean.
Hopefully an announcement on Fabry disease thus week? CHEERS!!!!!!!!
(217)
•••
askretka
X
View Profile
View Bullboard History
Post by
askretka
on Oct 14, 2024 5:23pm
Up 10.75 today
Hopefully it means a good announcement is coming soon.
(217)
•••
askretka
X
View Profile
View Bullboard History
Post by
askretka
on Sep 09, 2024 11:53am
Up over 12% at the moment
I think I made a good call accumulating this one for last couple months. More info to follow if I get the time. Cheers!!!@!
(217)
•••
askretka
X
View Profile
View Bullboard History
Post by
askretka
on Aug 18, 2024 7:28am
20 Nov to 22 November 2024
https://genetherapy-cns.com/
(217)
•••
askretka
X
View Profile
View Bullboard History
Post by
askretka
on Aug 08, 2024 10:55pm
Lots of potential here possibly 10 to 20x
Will post more later. In at 0.60 $ average for my fairly large position here. See Jeffries analyst report if possible. Their highest price target on this is 25$ we're at 0.92 now.
(9)
•••
MikeTester
X
View Profile
View Bullboard History
Post by
MikeTester
on Aug 03, 2024 4:46am
Sangamo Therapeutics, Inc. (NASDAQ:SGMO): Transforming Neuro
https://beyondspx.com/2024/08/02/sangamo-therapeutics-inc-nasdaqsgmo-transforming-neurology-with-groundbreaking-science/
(227)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jul 25, 2024 11:34am
What Data Should You Use to Trade Penny Stocks
JUST IN: $SGMO What Data Should You Use to Trade Penny Stocks2024-07-25 05:48:00 ET 3 Data Types to Use When Trading Penny Stocks Trading penny stocks can be a rewarding venture for those who
...more
(59)
•••
Nibinator
X
View Profile
View Bullboard History
Post by
Nibinator
on Jul 24, 2024 9:32am
BUY BUY BUY BUY BUY
Will hit 3$
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden